I've tried assessing the Amarin website on Yahoo, IV, Ihub and Google and it won't come up. And, the Lovaza site is down and Elan just got $3.25 billion from Biogen. Robert Graham was a high exec. at GSK before becoming chairman of Elan.
Maybe it's AZN or GSK or maybe we're still going to wait for the GIA numbers. If I were going to buy AMRN, I would want a little extra in a bid to provide for a good sales ramp. And, if I were buying AMRN, I would give the company that extra to pay for future sales. I think all parties know where sales are going and how Vascepa may just be more than for Tri's and LDL, but could be for diabetes, heart disease or other inflammation conditions. There's just too many ducks lined up for this to sit here and have to pay a lot more when a couple of months of huge sales numbers cascade in. Graham and von Eschenbach, if they buy it for Elan, know what's over the horizon and can push through the required approvals. JMO.